Bioriginal has further expanded into the USA by acquiring the assets of Softgel Co, a state-of-the-art softgel, squeeze tube and tincture manufacturing facility that specializes in encapsulation of human and pet nutrition products. 

With the support of our clients and partners, Bioriginal is:
• Expanding our global supply abilities,
• Eliminating the need to outsource soft gel production,
• Improving production efficiencies, and
• Enhancing our supply chain management.

Visit Bioriginal.com to learn more about the Softgel Co acquisition, what it means for our clients, and Bioriginal’s strategy to manage softgel, squeeze tube, and tincture manufacturing from seed or sea to shelf.